These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 1362616)

  • 1. Fluoxetine and trifluoperazine in human brain: a 19F-nuclear magnetic resonance spectroscopy study.
    Karson CN; Newton JE; Mohanakrishnan P; Sprigg J; Komoroski RA
    Psychiatry Res; 1992 Aug; 45(2):95-104. PubMed ID: 1362616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of psychoactive drugs in vivo in humans using 19F NMR spectroscopy.
    Komoroski RA; Newton JE; Karson C; Cardwell D; Sprigg J
    Biol Psychiatry; 1991 Apr; 29(7):711-4. PubMed ID: 2054443
    [No Abstract]   [Full Text] [Related]  

  • 3. In vivo 19F nuclear magnetic resonance spectroscopy of trifluorinated neuroleptics in the rat.
    Albert K; Rembold H; Kruppa G; Bayer E; Bartels M; Schmalzing G
    NMR Biomed; 1990 Jun; 3(3):120-3. PubMed ID: 2386658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Diagnostic principles for differential therapy of psychoses].
    Hell D; Bridler R
    Praxis (Bern 1994); 2001 May; 90(22):975-80. PubMed ID: 11450185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 19F nuclear magnetic resonance spectroscopy of neuroleptics: the first in vivo pharmacokinetics of trifluoperazine in the rat brain and the first in vivo spectrum of fluphenazine in the human brain.
    Bartels M; Günther U; Albert K; Mann K; Schuff N; Stuckstedte H
    Biol Psychiatry; 1991 Oct; 30(7):656-62. PubMed ID: 1958765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human brain fluoxetine concentrations.
    Karson CN; Newton JE; Livingston R; Jolly JB; Cooper TB; Sprigg J; Komoroski RA
    J Neuropsychiatry Clin Neurosci; 1993; 5(3):322-9. PubMed ID: 8369643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 19F magnetic resonance spectroscopy investigation in vivo of acute and steady-state brain fluvoxamine levels in obsessive-compulsive disorder.
    Strauss WL; Layton ME; Hayes CE; Dager SR
    Am J Psychiatry; 1997 Apr; 154(4):516-22. PubMed ID: 9090339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo 19F nuclear magnetic resonance of a monofluorinated neuroleptic in the rat.
    Günther U; Albert K
    NMR Biomed; 1993; 6(1):27-31. PubMed ID: 8096148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Drug treatment of functional psychotic disorders].
    Bridler R; Umbricht D; Hell D
    Praxis (Bern 1994); 2001 May; 90(22):981-6. PubMed ID: 11450186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo 19F spin relaxation and localized spectroscopy of fluoxetine in human brain.
    Komoroski RA; Newton JE; Cardwell D; Sprigg J; Pearce J; Karson CN
    Magn Reson Med; 1994 Feb; 31(2):204-11. PubMed ID: 8133756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of psychoactive drugs using 19F MR spectroscopy.
    Bartels M; Albert K
    J Neural Transm Gen Sect; 1995; 99(1-3):1-6. PubMed ID: 8579798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accumulation of fluoxetine and norfluoxetine in human brain during therapeutic administration.
    Renshaw PF; Guimaraes AR; Fava M; Rosenbaum JF; Pearlman JD; Flood JG; Puopolo PR; Clancy K; Gonzalez RG
    Am J Psychiatry; 1992 Nov; 149(11):1592-4. PubMed ID: 1415832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duration of lithium treatment and brain lithium concentration in patients with unipolar and schizoaffective disorder--a study with magnetic resonance spectroscopy.
    Riedl U; Barocka A; Kolem H; Demling J; Kaschka WP; Schelp R; Stemmler M; Ebert D
    Biol Psychiatry; 1997 Apr; 41(8):844-50. PubMed ID: 9099410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo 7Li nuclear magnetic resonance study of lithium pharmacokinetics and chemical shift imaging in psychiatric patients.
    Komoroski RA; Newton JE; Sprigg JR; Cardwell D; Mohanakrishnan P; Karson CN
    Psychiatry Res; 1993 Jun; 50(2):67-76. PubMed ID: 8378489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. D2 receptor occupancy following lurasidone treatment in patients with schizophrenia or schizoaffective disorder.
    Potkin SG; Keator DB; Kesler-West ML; Nguyen DD; van Erp TG; Mukherjee J; Shah N; Preda A
    CNS Spectr; 2014 Apr; 19(2):176-81. PubMed ID: 24073841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 19F-magnetic resonance spectroscopy and chemical shift imaging for schizophrenic patients using haloperidol decanoate.
    Sassa T; Suhara T; Ikehira H; Obata T; Girard F; Tanada S; Okubo Y
    Psychiatry Clin Neurosci; 2002 Dec; 56(6):637-42. PubMed ID: 12485307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered phospholipid metabolism in schizophrenia: a phosphorus 31 nuclear magnetic resonance spectroscopy study.
    Weber-Fahr W; Englisch S; Esser A; Tunc-Skarka N; Meyer-Lindenberg A; Ende G; Zink M
    Psychiatry Res; 2013 Dec; 214(3):365-73. PubMed ID: 24045051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One-dimensional chemical shift imaging of fluorinated neuroleptics in rat brain in vivo by 19F NMR rotating frame zeugmatography.
    Nakada T; Kwee IL
    Magn Reson Imaging; 1989; 7(5):543-5. PubMed ID: 2575203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implementation of a rational pharmacotherapy intervention for inpatients at a psychiatric department.
    Sorensen L; Nielsen B; Stage KB; Brøsen K; Damkier P
    Nord J Psychiatry; 2008; 62(3):242-9. PubMed ID: 18622885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proton magnetic resonance spectroscopy study of brain metabolite changes after antipsychotic treatment.
    Szulc A; Galinska B; Tarasow E; Waszkiewicz N; Konarzewska B; Poplawska R; Bibulowicz D; Simonienko K; Walecki J
    Pharmacopsychiatry; 2011 Jun; 44(4):148-57. PubMed ID: 21710405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.